ETF · SPDR · XBI

State Street SPDR S&P Biotech ETF

State Street SPDR S&P Biotech ETF (XBI) is an ETF from SPDR that tracks the S&P Biotechnology Select Industry Index index. Its ongoing charge is 0.35% a year and it holds $10.2bn in assets. The fund uses physical replication, is distributing, is domiciled in United States.

XBI in figures

Assets
$10.2bn
Ongoing charge (TER)
0.35%
Holdings
165
Weight of the ten largest
18.4%
Dividend yield
0.1%
Return, year to date (USD)
+23.6%
Return, 1 year (USD)
+35.1%
Return, 3 years a year (USD)
+28.8%
Return, 5 years a year (USD)
+3.7%
Volatility, 3 years (USD)
28.1%

Figures as of 13 November 2026. Past performance does not predict future returns. Information only, not investment advice.

Fund facts

Issuer
SPDR
Index
S&P Biotechnology Select Industry Index
Asset class
Equity, Sector
Region
US
Replication
Physical
Income
distributing
Domicile
United States
Currency hedged
No
Launched
6 February 2006
ISIN
US78464A8707

Largest holdings

MODERNA INC2.7%
EXELIXIS INC1.8%
AMGEN INC1.8%
BIOGEN INC1.8%
GILEAD SCIENCES INC1.8%
ABBVIE INC1.8%
HALOZYME THERAPEUTICS INC1.8%
REGENERON PHARMACEUTICALS1.7%
UNITED THERAPEUTICS CORP1.7%
SPYRE THERAPEUTICS INC1.7%

Sectors

Healthcare99.3%
Financial Services0.7%

Countries

United States96.8%
Switzerland1.4%
United Kingdom1.3%
Netherlands0.5%
Ireland0.1%
China0.0%